Stimulus dependence of the action of small-molecule inhibitors in the CD3/CD28 signalling network

被引:1
作者
Koehler, Karsten [2 ]
Ganser, Alexander [1 ]
Andre, Thomas [2 ]
Roth, Guenter [2 ]
Grosse-Hovest, Ludger [3 ]
Jung, Gundram [3 ]
Brock, Roland [1 ,2 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Biochem, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands
[2] Univ Tubingen, Interfac Inst Cell Biol, Dept Mol Biol, D-72076 Tubingen, Germany
[3] Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany
关键词
cell activation; drug development; immunology; signal transduction; T lymphocytes;
D O I
10.1002/cmdc.200800134
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cells in the body are exposed simultaneously to a multitude of various signals. Inside a cell, molecular signalling networks integrate this information into a physiologically meaningful response. Interestingly, in the cellular testing of drug candidates, this complexity is largely ignored. Compounds are tested for cells that are challenged with one stimulus only. The activation of T lymphocytes through engagement of the T cell receptor (TCR)-CD3 complex and CD28 coreceptor is a prominent example for a cellular response that depends on the integration of signals. We investigated the cellular response characteristics of this network at different strengths of receptor and coreceptor activation. A novel cellular microarray-based approach, in which various combinations of antibodies directed against the CD3 complex and CD28 were spotted, was employed for analysing the stimulus dependence of activation of the transcription factor NFAT and actin reorganisation. For both responses, quantitative differences in inhibitor activity were observed. Remarkably, for IL-2 expression, which was detected by standard ELISA, low doses of the Src-family kinase inhibitor PP2 strongly potentiated IL-2 expression at high-level, but not at low-level, CD28 co-engagement. Therefore, for a physiologically highly relevant signalling network, the cellular response might vary qualitatively with only quantitative variations of a stimulus. This level of complexity should be considered in early cellular drug testing.
引用
收藏
页码:1404 / 1411
页数:8
相关论文
共 34 条
  • [1] CD28-mediated co-stimulation: A quantitative support for TCR signalling
    Acuto, O
    Michel, F
    [J]. NATURE REVIEWS IMMUNOLOGY, 2003, 3 (12) : 939 - 951
  • [2] The specificities of protein kinase inhibitors: an update
    Bain, J
    McLauchlan, H
    Elliott, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2003, 371 : 199 - 204
  • [3] THE CD4 AND CD8 ANTIGENS ARE COUPLED TO A PROTEIN-TYROSINE KINASE (P56LCK) THAT PHOSPHORYLATES THE CD3 COMPLEX
    BARBER, EK
    DASGUPTA, JD
    SCHLOSSMAN, SF
    TREVILLYAN, JM
    RUDD, CE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (09) : 3277 - 3281
  • [4] T cell receptor ligation induces the formation of dynamically regulated signaling assemblies
    Bunnell, SC
    Hong, DI
    Kardon, JR
    Yamazaki, T
    McGlade, CJ
    Barr, VA
    Samelson, LE
    [J]. JOURNAL OF CELL BIOLOGY, 2002, 158 (07) : 1263 - 1275
  • [5] Dynamic actin polymerization drives T cell receptor-induced spreading: A role for the signal transduction adaptor LAT
    Bunnell, SC
    Kapoor, V
    Trible, RP
    Zhang, WG
    Samelson, LE
    [J]. IMMUNITY, 2001, 14 (03) : 315 - 329
  • [6] NEGATIVE REGULATION OF T-CELL RECEPTOR SIGNALING BY TYROSINE PROTEIN-KINASE P50(CSK)
    CHOW, LML
    FOURNEL, M
    DAVIDSON, D
    VEILLETTE, A
    [J]. NATURE, 1993, 365 (6442) : 156 - 160
  • [7] SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1
    CUENDA, A
    ROUSE, J
    DOZA, YN
    MEIER, R
    COHEN, P
    GALLAGHER, TF
    YOUNG, PR
    LEE, JC
    [J]. FEBS LETTERS, 1995, 364 (02) : 229 - 233
  • [8] A small molecule-kinase interaction map for clinical kinase inhibitors
    Fabian, MA
    Biggs, WH
    Treiber, DK
    Atteridge, CE
    Azimioara, MD
    Benedetti, MG
    Carter, TA
    Ciceri, P
    Edeen, PT
    Floyd, M
    Ford, JM
    Galvin, M
    Gerlach, JL
    Grotzfeld, RM
    Herrgard, S
    Insko, DE
    Insko, MA
    Lai, AG
    Lélias, JM
    Mehta, SA
    Milanov, ZV
    Velasco, AM
    Wodicka, LM
    Patel, HK
    Zarrinkar, PP
    Lockhart, DJ
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (03) : 329 - 336
  • [9] Pharmacologic profiling of transcriptional targets deciphers promoter logic
    Freebern, WJ
    Haggerty, CM
    Montano, I
    McNutt, MC
    Collins, I
    Graham, A
    Chandramouli, GVR
    Stewart, DH
    Biebuyck, HA
    Taub, DD
    Gardner, K
    [J]. PHARMACOGENOMICS JOURNAL, 2005, 5 (05) : 305 - 323
  • [10] High-content screening: A new approach to easing key bottlenecks in the drug discovery process
    Giuliano, KA
    DeBiasio, RL
    Dunlay, RT
    Gough, A
    Volosky, JM
    Zock, J
    Pavlakis, GN
    Taylor, DL
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 1997, 2 (04) : 249 - 259